Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022 .